Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey

Abstract

Objectives: The goal of therapy in chronic hepatitis B infection (CHB) is to impede liver injury by suppressing viral rep- lication. The study was aimed to determine the eficacy of tenofovir (TDF) in CHB infection for 48 weeks. Materials and methods: We retrospectively analyzed the data of 45 CHB patients treated by tenofovir. The patients were divided into two groups based on their hepatitis B e antigen status (HBeAg). Those who were eligible to therapy received TDF 300 mg once daily for 48 weeks. Serum alanine aminotransferase levels (ALT), hepatitis B virus DNA (HBV DNA), and viral serological markers were checked at three-month intervals. Liver biopsy scores were determined in all patients. Results: The mean age &plusmn; standard deviation (SD) was 35.8 &plusmn; 17.0 years, 26 (57.8 %) were male, and seven patients (15.5%) were treatment-experienced by a nucleos(t)ide analogue before TDF. HBeAg was positive in 17 (37.8%) patients. At week 48 among HBeAg positive (HBeAg +) patients\' biochemical and virological response rates at month-3, -6 and -12 were 64.7%, and 100%, 70.6%, and 94.1%, and 88.2%, and 64.7%, respectively. The serological response in HBeAg + patients was 29.4%. For HBeAg negative (HBeAg -) patients; biochemical, and virological response rates were 64.3%, and 96.4% at month 3; 82.1%, and 96.4% at month 6; and 100%, and 85.7% at month 12, respectively. At week 48 both groups had signiicant virological response (p<0.001). Conclusion: Treatment in CHB with TDF leads to HBV DNA suppression without evident resistance for 48-week, and is well tolerated.

Keywords

• -

Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey

Öz

Anahtar Kelimeler

• -

References

1. Akarca US. Treatment of chronic hepatitis B. Turkiye Klinikleri J Gastroenterohepatol-Special Topics 2010; 3:53-63.
2. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
3. Kandemir O, Polat G, Sayici T, Goruroglu O, Tasdelen B. Eval- uation of MHC class 2 alleles in chronic hepatitis B patients and inactive hepatitis B carriers. Turkiye Klinikleri J Med Sci 2010; 30:1317-1324.
4. Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Ther Adv Gastroenterol 2010; 3:107-119.
5. Akhan S, Gurbuz Y, Uckardes H. The association between biochemical parameters and extent of disease in patients with chronic hepatitis B. Turkiye Klinikleri J Med Sci 2009; 29:36-41.
6. Tsang PS, Trinh H, Garcia RT, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol 2008; 6:569-574.
7. Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv Ther 2009; 26:155-169.
8. Kim ES, Seo YS, Keum B, et al. The HBV DNA cutoff value for discriminating patients with HBeAg negative chronic hepa- titis B from inactive carriers. Hepat Mon 2011; 11:351-357.

9. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long- term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751
11. Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabo- lism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-2477.
12. Zhao SS, Tang LH, Dai XH, et al. Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: a systematic review. Virol J 2011; 8:1-9.
13. Sheldon J, Camino N, Rodes B, et al. Selection of hepati- tis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734.
14. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir-resistant mutations. J Hepatol 2008; 48:391-398.
15. Mistik R. Türkiye’de viral hepatitlerin epidemiyolojisi: yayınla- rın irdelenmesi. Ed: Tabak F, Balık İ, Tekeli E, In: Viral hepatit 2007, İstanbul: Oban Matbaası, 1. Baskı, Viral Hepatitle Sa- vaşım Derneği, 2005:10-50.